Ranbaxy: Ranbaxy Continues to Add Value and Utility to US Product Portfolio

Published Online: Tuesday, July 23, 2013
Follow Pharmacy_Times:
Ranbaxy Laboratories Limited entered the U.S. generic pharmaceutical market in 1995 introducing its first product under the Ranbaxy Pharmaceuticals Inc. label in January 1998. Since then, RPI's generic line has experienced consistent growth and expansion over the years. To date, Ranbaxy has filed with the U.S. FDA 145 Abbreviated New Drug Applications (ANDAs) and has approval for 103 applications with 42 pending final approval. Today, RPI remains committed to this effort, and has a goal of submitting a number of ANDAs on a yearly basis in order to continue to expand the depth and breathe of its product portfolio. This fits strategically with RPI’s long-term strategy that features an extensive product portfolio of high quality and affordable generic product formulations that are readily accessible through established distribution channels to patients and prescribers. Plans are in place to continue to add utility and value to the product portfolio to meet the needs of the U.S. healthcare system.

Ranbaxy's growth and success can be attributed to being vertically integrated. That is to have the ability to develop a product in the lab, and ultimately to commercialize the product formulation in the market. This means that Ranbaxy is involved in all aspects of product development from producing the active ingredient, filing an ANDA, manufacturing the finished dosage form, and marketing and distributing this product to pharmacies throughout the U.S. Being vertically integrated results in an efficient and reliable process allowing product to be available in a timely fashion at a competitive price.


Ranbaxy has a state of the art R&D campus.





Ranbaxy markets over a 100 FDA-approved products.

RPI’s product portfolio features anti-infective agents, as well as a number of compounds in a wide variety of therapeutic areas including cardiovascular, central nervous system, analgesia, gastrointestinal and metabolic diseases/conditions. These generic products are manufactured as capsules and tablets, and are manufactured within cGMP facilities that are FDA inspected and approved. Ultimately these products are available in the market through various chain and independent pharmacies, and other classes of trade such as wholesalers, generic distributors and hospitals.




Related Articles
Patients with chronic cardiovascular disease who receive automated reminders for their prescription blood pressure and cholesterol medications are more likely to refill those drugs.
A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
The FDA is taking a look at a trial that showed 30 months of dual antiplatelet blood-thinning therapy decreased the risk of heart attack and clot formation in stents, yet increased the overall risk of death compared with 12 months of the treatment.
Latest Issues
$auto_registration$